Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy

References

• Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol. 1985;249(3 Pt 2):F324--F337
   PubMed Web of Science ®Google Scholar
• Hayslett JP, Kashgarian M, Epstein FH. Functional correlates of compensatory renal hypertrophy. J Clin Invest. 1968;47:774–799
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33–45
   PubMed Web of Science ®Google Scholar
• Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br J Clin Pharmacol. 1995;39:597–603
   PubMed Web of Science ®Google Scholar
• Fabrizii V, Thalhammer F, Hörl WH. Aminoglycoside-induced nephrotoxicity. Wien Klin Wochenschr. 1997;109:830–835
   PubMedGoogle Scholar
• Gluhovschi G, Bozdog G, Schiller A, et al. Urinary tract infection in patients with solitary kidney. Facta Universitatis. 1998;5:37–39
   Google Scholar
• Skálová S. The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove). 2005;48:75–80
   PubMedGoogle Scholar
• Yu H, Yanagisawa Y, Forbes MA, Cooper EH, Crockson RA, MacLennan IC. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol. 1983;36:253–259
   PubMed Web of Science ®Google Scholar
• Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361–368
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease Improving Outcomes (KDIGO). Kidney Int. 2005;67:2098–2100
   Google Scholar
• Tekin N, Kural N, Uslu S. N-acetyl-beta-D-glucosaminidase excretion in patients with unilateral renal agenesis or nephrectomy in childhood. Turk J Pediatr. 1996;38:485–490
   PubMedGoogle Scholar
• Gadalean F, Kaycsa A, Gluhovschi G, et al. Is the urinary biomarkers assessment a non-invasive approach to tubular lesions of the solitary kidney? Ren Fail. 2013;35:1358--1364
   Google Scholar
• Stefanowicz J, Owczuk R, Kałużyńska B, et al. Renal function and solitary kidney disease: Wilms tumour survivors versus patients with unilateral renal agenesis. Kidney Blood Press Res. 2012;35:174–181
   PubMedGoogle Scholar
• Gluhovschi G, Velciov S, Kaycsa A, et al. Utilization of urinary NAG elimination in the evaluation and nephrotoxicity of UTI treatment with amikacin. Nieren- und Hochdruckkrankheiten. 2004;33:285–288
   Google Scholar
• Gluhovschi G, Velciov S, Kaycsa A, et al. Tubular lesions during renal colic with and without associated urinary tract infections(UTIs) evaluated by the determination of urinary N-acetyl-β-D glucosaminidase (NAG). Nieren-und Hochdruckkrankheiten 2005;10:S.458–S.463
   Google Scholar
• Chan MK. N-acetyl-beta-glucosaminidase in the localization of the site of urinary tract infections. Singapore Med J. 1990;31:135–137
   PubMedGoogle Scholar
• Belli A, Scalercio F, Martino F, et al. Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood. Clinical study of 168 children. Minerva Pediatr. 1996;48:503–507
   PubMedGoogle Scholar
• Bazzi C, Petrini C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002;17:1890–1896
   PubMed Web of Science ®Google Scholar
• Mishra OP, Jain P, Srivastava P, Prasad R. Urinary N-acetyl-beta-D glucosaminidase (NAG) level in idiopathic nephrotic syndrome. Pediatr Nephrol. 2012;27:589–596
   PubMedGoogle Scholar
• Gluhovschi C, Velciov S, Kaycsa A, et al. The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. Immunopharmacol Immunotoxicol. 2012;34:163–169
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Wehrle L, Zimmerhackl LB. Renal tubular dysfunction following treatment with anti-epileptic drugs. Eur J Pediatr. 1994;153:855–858
   PubMed Web of Science ®Google Scholar
• Donadio C, Tramonti G, Lucchesi A, Giordani R, Lucchetti A, Bianchi C. Tubular toxicity is the main renal effect of contrast media. Ren Fail. 1996;18:647–656
   PubMed Web of Science ®Google Scholar
• Franke RM, Kosloske AM, Lancaster CS, et al. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res. 2010;16:4198–4206
   PubMed Web of Science ®Google Scholar
• Moriguchi J, Inoue Y, Kamiyama S, et al. N-acetyl-beta-D-glucosaminidase (NAG) as the most sensitive marker of tubular dysfunction for monitoring residents in non-polluted areas. Toxicol Lett. 2009;190:1–8
   PubMedGoogle Scholar
• Piwowar A, Knapik-Kordecka M, Fus I, Warwas M. Urinary activities of cathepsin B, N-acetyl-beta-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2006;12:CR210–CR214
   PubMedGoogle Scholar
• Johnston ID, Jones NF, Scoble JE, Yuen CT, Price RG. The diagnostic value of urinary enzyme measurements in hypertension. Clin Chim Acta. 1983;133:317–325
   PubMed Web of Science ®Google Scholar
• Kotanko P, Margreiter R, Pfaller W. Reduced renal allograft survival is related to low urinary N-acetyl-beta-D-glucosaminidase excretion during the first posttransplant month. Transplantation. 1996;61:388–392
   PubMed Web of Science ®Google Scholar
• Everaert K, Raes A, Hoebeke P, et al. Combined use of urinary alpha-1-microglobulin and 99mTc DMSA scintigraphy in the diagnosis and follow-up of acute pyelonephritis and cystitis in children. Eur Urol. 1998;34:486–491
   PubMed Web of Science ®Google Scholar
• Herget-Rosenthal S, Poppen D, Hüsing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem. 2004;50:552–558
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43:727–737
   PubMed Web of Science ®Google Scholar
• Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci. 2011;119:245–256
   PubMed Web of Science ®Google Scholar
• Verpooten GA, Tulkens PM, Molitoris BA. Aminoglycosides and vancomycin. In: De Broe ME, Porter GA, Bennett WM, Verpooten GA, eds. Clinical Nephrotoxins. 2nd ed. Dordrecht, The Netherlands: Kluver Academic Publishers; 2003:151–170
   Google Scholar
• Queiroz FP, Oliveira MM, Rocha H. Tobramycin in chronic recurrent urinary tract infections. Am J Med Sci. 1976;271:29–34
   PubMedGoogle Scholar
• Whiting PH, Brown PA. The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Ren Fail. 1996;18:899–909
   PubMed Web of Science ®Google Scholar
• Wiland P, Szechciński J. Proximal tubule damage in patients treated with gentamicin or amikacin. Pol J Pharmacol. 2003;55:631–637
   PubMedGoogle Scholar
• Chapelsky MC, Nix DE, Cavanaugh JC, Wilton JH, Norman A, Schentag JJ. Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers. Drug Saf. 1992;7:304–309
   PubMed Web of Science ®Google Scholar
• Carver MP, Monteiro-Riviere NA, Brown TT, Riviere JE. Dose-response studies of gentamicin nephrotoxicity in rats with experimental renal dysfunction. II. Polyvinyl alcohol glomerulopathy. Toxicol Appl Pharmacol. 1985;80:264–273
   PubMedGoogle Scholar
• Hügli R, Artho G, Wiesmann UN, Peheim E, Schaad UB, Bianchetti MG. Assessment of the nephrotoxicity of amikacin in patients with cystic fibrosis. Schweiz Med Wochenschr. 1992;122:930–935
   PubMedGoogle Scholar
• Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38:14–19
   PubMed Web of Science ®Google Scholar
• Wiesmann U, Peheim E, Colombo JP. Excretion of N-acetyl-beta-D-glucosaminidase in the urine of children with type I juvenile diabetes mellitus and of patients treated with the aminoglycoside amikacin. Klin Wochenschr. 1989;67(Suppl 17):40–43
   PubMedGoogle Scholar
• Coscia A, Maiorca D, Martano C, et al. Use of netilmicin once or twice daily in preterm newborns: evaluation of nephrotoxicity by urinary alpha-1-microglobulin and retinol binding protein. J Chemother. 2008;20:324–326
   PubMed Web of Science ®Google Scholar